• No results found

Rx for CHANGE

N/A
N/A
Protected

Academic year: 2021

Share "Rx for CHANGE"

Copied!
148
0
0

Loading.... (view fulltext now)

Full text

(1)

Rx for CHANGE

Tobacco Cessation in Respiratory Care

(2)

TRAINING OVERVIEW

Epidemiology of Tobacco Use

Impact of Tobacco Use on Respiratory Health

Nicotine Pharmacology & Addiction

Assisting Patients with Quitting

Medications for Smoking Cessation

(3)

EPIDEMIOLOGY

of TOBACCO USE

(4)

is the chief, single,

avoidable cause of death in our society and the most

important public health issue of our time.”

C. Everett Koop, M.D., former U.S. Surgeon General

“CIGARETTE SMOKING…

All forms of tobacco are harmful.

(5)

TRENDS in ADULT SMOKING, by SEX—U.S., 1955–2015

Trends in cigarette current smoking among persons aged 18 or older

Graph provided by the Centers for Disease Control and Prevention. 1955 Current Population Survey;

1965–2015 NHIS. Estimates since 1992 include some-day smoking.

Percent

69% want to quit

53% tried to quit in the past year

Males

Females

16.7%

13.6%

15.1% of adults are current

smokers

Year

(6)

ANNUAL U.S. DEATHS ATTRIBUTABLE to SMOKING, 2005–2009

33%

27%

23%

9%

7%

<1%

Cardiovascular & metabolic diseases 160,600

Lung cancer 130,659

Pulmonary diseases 113,100

Second-hand smoke 41,280

Cancers other than lung 36,000

Other 1,633

Percent of all smoking- attributable deaths

TOTAL: >480,000 deaths annually

U.S. Department of Health and Human Services (USDHHS). (2014).

The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General.

(7)

2014 REPORT of the SURGEON GENERAL:

HEALTH CONSEQUENCES OF SMOKING

Cigarette smoking is causally linked to diseases of nearly all organs of the body, diminished health status, and harm to the fetus.

Additionally, smoking has many adverse effects on the body, such as causing inflammation and impairing immune function.

Exposure to second-hand smoke is causally linked to cancer, respiratory, and cardiovascular diseases, and to adverse effects on the health of infants and children.

Disease risks from smoking by women have risen over the last 50 years and for many tobacco-related diseases are now equal to those for men.

MAJOR DISEASE-RELATED CONCLUSIONS:

U.S. Department of Health and Human Services (USDHHS). (2014).

The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General.

(8)

HEALTH CONSEQUENCES of SMOKING

Cancers

Bladder/kidney/ureter

Blood (acute myeloid leukemia)

Cervix

Colon/rectum

Esophagus/stomach

Liver

Lung

Oropharynx/larynx

Pancreatic

Pulmonary diseases

Asthma

COPD

Pneumonia/tuberculosis

Chronic respiratory symptoms

Cardiovascular diseases

Aortic aneurysm

Coronary heart disease

Cerebrovascular disease

Peripheral vascular disease

Reproductive effects

Reduced fertility in women

Poor pregnancy outcomes (e.g., congenital defects, low birth weight, preterm delivery)

Infant mortality

Other: cataract, diabetes (type 2), erectile dysfunction, impaired immune function, osteoporosis, periodontitis, postoperative complications, rheumatoid arthritis

U.S. Department of Health and Human Services (USDHHS). (2014).

The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General.

(9)

COMPOUNDS in TOBACCO SMOKE

Carbon monoxide

Hydrogen cyanide

Ammonia

Benzene

Formaldehyde

Nicotine

Nitrosamines

Lead

Cadmium

Polonium-210

An estimated 4,800 compounds in tobacco smoke, including 16 proven human carcinogens

Gases Particles

Nicotine is the addictive component of tobacco products, but it does NOT cause the ill health effects of tobacco use.

(10)

FDA REGULATION of TOBACCO PRODUCTS

The FDA Center for Tobacco Control Products is responsible for regulation of:

Cigarettes

Cigarette tobacco

Roll-your-own tobacco

Smokeless tobacco

E-cigarettes*

*Not a tobacco product.

(11)

ELECTRONIC CIGARETTES (“e-cigarettes”)

Battery-operated devices

Known to contain nicotine (0–36 mg/ml), flavoring (e.g., tobacco, fruit, chocolate, mint, cola), propylene glycol, and glycerin

Battery warms cartridge; user inhales nicotine vapor or “smoke”

Heating element vaporizes liquid at temperatures of 65–120°C

Not labeled with health warnings

(12)

Nicotine is highly addictive and can be harmful.

Refill cartridges with high concentrations of nicotine are a poisoning risk, especially in children.

Propylene glycol may cause respiratory irritation and increase the risk for asthma.

Glycerin may cause lipoid pneumonia on inhalation.

Carcinogenic substances are found in some aerosols.

Use of e-cigarettes leads to emission of propylene glycol, particles, nicotine, and carcinogens into indoor air.

Long-term safety of second-hand exposure to e-cigarette aerosols is unknown.

ELECTRONIC CIGARETTES:

Potential Health Risks

(13)

Can reduce the desire (craving) to smoke cigarettes and alleviate nicotine withdrawal symptoms

Some smokers reduce the number of cigarettes

smoked or quit smoking as a result of using e- e-cigarettes

Have not been proven effective as an aid for sustained smoking cessation

Concern about “gateway” to tobacco use in adolescents

ELECTRONIC CIGARETTES:

Current Trends and Evidence

Long-term safety and cessation efficacy data are lacking.

(14)

HERMAN ® is reprinted with permission from LaughingStock Licensing Inc., Ottawa, Canada

All rights reserved.

(15)

U.S. Department of Health and Human Services (USDHHS). (2006).

The Health Consequences of Involuntary Exposure to Tobacco Smoke: Report of the Surgeon General.

There is no safe level of second-hand

smoke.

Second-hand smoke causes premature death and disease in nonsmokers (children and adults).

Children:

Increased risk for sudden infant death syndrome

(SIDS), acute respiratory infections, ear problems, and more severe asthma

2006 REPORT of the SURGEON GENERAL:

INVOLUNTARY EXPOSURE to TOBACCO SMOKE

Respiratory symptoms and slowed lung growth if parents smoke

Adults:

Immediate adverse effects on cardiovascular system

Increased risk for coronary heart disease and lung cancer

Millions of Americans are exposed to smoke in their homes/workplaces.

Indoor spaces: eliminating smoking fully protects nonsmokers; separating smoking areas, cleaning the air, and ventilation are ineffective.

(16)

EPIDEMIOLOGY of TOBACCO USE: SUMMARY

Fewer than one in five adults are current smokers; smoking prevalence varies by sociodemographic characteristics.

Nearly half a million U.S. deaths are attributable to smoking annually.

Smoking costs the U.S. an estimated $288.9 billion annually.

For the individual, a smoking a pack-a-day costs $2,256 annually, plus associated health-care costs.

At any age, there are benefits to quitting smoking.

The biggest opponent to tobacco control efforts is the tobacco industry.

(17)

IMPACT of TOBACCO USE

on RESPIRATORY HEALTH

(18)

SMOKING and RESPIRATORY DISEASE

Acute respiratory diseases: increased risk, duration, severity

Upper respiratory tract

Rhinitis, laryngitis, pharyngitis, sinusitis

Lower respiratory tract

Bronchitis, pneumonia

Chronic respiratory diseases

Asthma

Chronic obstructive pulmonary disease (COPD)

Tuberculosis

Lung cancer

(19)

PNEUMONIA

Smokers exhibit increased risk for pneumonia

Biologic mechanisms:

Damages cilia

Increases permeability of airway epithelium

Enables infection to more easily enter lungs

Reduces overall immune response

Risk increases as number of cigarettes smoked increases

Risk returns to baseline after ten years of not smoking

(20)

ASTHMA

An estimated 21% of patients with asthma are current smokers

Smoking increases the risk of asthma exacerbations in adults

Reduced response to treatment with inhaled and systemic corticosteroids

Patients with asthma should not smoke.

(21)

ASTHMA: IN UTERO EXPOSURE

Maternal smoking results in infant/child:

1.8 times increased likelihood of developing asthma as well as lifetime history of wheezing

3.6 times increased likelihood of severe asthma

Deficits in lung function up to age 6

Reduction in forced expiratory flow and suppression of child’s:

formation of the alveoli

functional residual capacity

tidal flow volume

(22)

CHRONIC OBSTRUCTIVE

PULMONARY DISEASE (COPD)

Characterized by airflow limitation (not fully reversible)

Progressive airflow limitation associated with abnormal inflammatory lung response to noxious particles or gases

Characteristic symptoms: cough, sputum production, dyspnea

COPD mortality has increased dramatically in the past 50 years; currently, more women than men die due to COPD

3rd leading cause of death in the United States

U.S. Department of Health and Human Services (USDHHS). (2014). The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General, p. 385.

The primary risk factor for COPD is tobacco smoking.

(23)

COPD: BIOLOGIC MECHANISMS

Tobacco smoke induces inflammation and damage to pulmonary tissue through

Release of inflammatory cells and mediators

Imbalance between proteases and antiproteases

Oxidative stress

The best treatment for COPD is to quit smoking.

Medications simply manage the symptoms.

(24)

TUBERCULOSIS

Smoking is a causal risk factor for contracting TB

2.0–2.6 increased risk compared to nonsmokers

Risk increases with

Number of cigarettes smoked

Duration of smoking

Exposure to second-hand smoke increases risk for TB in children

Smoking is causally associated with recurrent TB

and TB-related mortality

(25)

SMOKING and LUNG CANCER

Lung cancer accounts for an estimated 27% of smoking-attributable deaths

Smoking cessation yields meaningful improvements in all forms of cancer treatment (surgery,

chemotherapy, radiation)

Early-stage non-small-cell lung cancer:

5-year survival rates are up to 70% in those who quit, versus 33% in those who do not

Patients who continue to smoke are nearly 2X as likely to have a recurrence and more than 4X as likely to develop a second primary tumor

(26)

SMOKING and LUNG CANCER

(cont’d)

Despite the benefits of quitting, lung cancer patients have a high prevalence of smoking and relapse to tobacco use

About 50% of lung cancer patients who quit resume smoking

39% of lung cancer physicians actively provide cessation assistance to their patients

(27)

EFFECT of SECOND-HAND SMOKE on CYSTIC FIBROSIS PATIENTS

For every 10 cigarettes/day smoked in household:

FEV1 decreased by 4%

FVC decreased by 3%

Increase in coughing and severity of respiratory illnesses

Fivefold increase in pulmonary-related

hospitalizations

(28)

THIRD-HAND SMOKE

The residual chemicals from smoking that deposit on clothing, hair, skin, and other surfaces

Contains more than 250 harmful chemicals; can last for days or weeks

Can cause respiratory irritation and is particularly dangerous to infants

While most adults know that second-hand smoke is

harmful, few know about third-hand smoke

(29)

SMOKING and POSTOPERATIVE COMPLICATIONS

Respiratory complications

Pneumonia

Respiratory failure

Surgical wound complications

Delayed healing

Wound dehiscence

Infection

Scarring

(30)

CARBON MONOXIDE (CO):

PULSE OXIMETRY

The CO from tobacco smoke binds to hemoglobin, taking the place of oxygen

Oximeters cannot differentiate between hemoglobin molecules that are saturated in oxygen versus those carrying CO

Readings will be higher

Effects last for up to 4 hours after smoking a cigarette

Arterial blood gas assessment is more accurate for determining oxygen saturation in patients who smoke

(31)

QUITTING:

HEALTH BENEFITS

Lung cilia regain normal function

Ability to clear lungs of mucus increases

Coughing, fatigue, shortness of breath decrease

Excess risk of CHD decreases to half that of a continuing smoker

Risk of stroke is reduced to that of people who have never

smoked Lung cancer death rate

drops to half that of a continuing smoker Risk of cancer of mouth,

throat, esophagus, bladder, kidney, pancreas decrease

Risk of CHD is similar to that of people who have never smoked

2 weeks to 3 months

1 to 9 months

1 year

5 years

10 years

after 15 years

Time Since Quit Date Circulation improves

Walking becomes easier Lung function increases

(32)

BENEFICIAL EFFECTS of

QUITTING: PULMONARY EFFECTS

Reprinted with permission. Fletcher & Peto. (1977). BMJ 1(6077):1645–1648.

Disability

Death

Smoked regularly and susceptible to effects of smoke

Never smoked or not susceptible to smoke

Stopped smoking at 45 (mild COPD)

Stopped smoking at 65 (severe COPD) 25

FEV 1 (% of value at age 25)

25 50 75 100

0

50 75

Age (years)

COPD = chronic obstructive pulmonary disease

AT ANY AGE, there are pulmonary benefits of quitting.

(33)

IMPACT of TOBACCO USE:

SUMMARY

Exposure to tobacco smoke significantly compromises pulmonary health

Acute and chronic disease rates are elevated in persons of all ages who are exposed to tobacco smoke

There is no safe level of exposure to second-hand smoke, and third-hand smoke can be harmful to patients with

respiratory disorders

Quitting smoking can improve, reverse, or halt the

progression of many tobacco-related respiratory diseases and improve surgical outcomes

(34)

NICOTINE PHARMACOLOGY and

PRINCIPLES of ADDICTION

(35)

WHAT IS ADDICTION?

”Compulsive drug use, without medical purpose, in the face of

negative consequences”

Alan I. Leshner, Ph.D.

Former director, National Institute on Drug Abuse National Institutes of Health

Nicotine addiction is a chronic condition with a biological basis.

(36)

TOBACCO DEPENDENCE:

A 2-PART PROBLEM

Tobacco Dependence

Treatment should address the physiological and behavioral aspects of dependence.

Physiological Behavioral

Treatment Treatment

The addiction to nicotine

Medications for cessation

The habit of using tobacco

Behavior change program

(37)

NICOTINE DISTRIBUTION

Henningfield et al. (1993). Drug Alcohol Depend 33:23–29.

Arterial

Venous

Nicotine reaches the brain within 10–20 seconds.

(38)

Nicotine enters brain

Stimulation of

nicotine receptors Dopamine release

DOPAMINE REWARD PATHWAY

Prefrontal cortex

Nucleus accumbens

Ventral tegmental

area

(39)

Irritability/frustration/anger

Anxiety

Difficulty concentrating

Restlessness/impatience

Depressed mood/depression

Insomnia

Impaired performance

Increased appetite/weight gain

Cravings

NICOTINE PHARMACODYNAMICS:

WITHDRAWAL EFFECTS

Hughes. (2007). Nicotine Tob Res 9:315–327.

Most symptoms manifest within the first 1–2 days,

peak within the first week, and subside within

2–4 weeks.

(40)

BIOLOGY of NICOTINE ADDICTION:

ROLE of DOPAMINE

Nicotine stimulates dopamine release

Repeat administration

Tolerance develops

Discontinuation leads to withdrawal symptoms.

Pleasurable feelings

Nicotine addiction

is not just a bad habit.

Benowitz. (2008). Clin Pharmacol Ther 83:531–541.

(41)

NICOTINE ADDICTION

Tobacco users maintain a minimum serum nicotine concentration in order to

Prevent withdrawal symptoms

Maintain pleasure/arousal

Modulate mood

Users self-titrate nicotine intake by

Smoking/dipping more frequently

Smoking more intensely

Obstructing vents on low-nicotine brand

cigarettes

Benowitz. (2008). Clin Pharmacol Ther 83:531–541.

(42)

CLOSE TO HOME © 2000 John McPherson.

Reprinted with permission of UNIVERSAL PRESS SYNDICATE.

All rights reserved.

(43)

FACTORS CONTRIBUTING to TOBACCO USE

Individual

Sociodemographics

Genetic predisposition

Coexisting medical conditions

Environment

Tobacco advertising

Conditioned stimuli

Social interactions

Pharmacology

Alleviation of withdrawal symptoms

Weight control

Pleasure, mood modulation

Tobacco

Use

(44)

NICOTINE PHARMACOLOGY and ADDICTION: SUMMARY

Tobacco products are effective delivery systems for the drug nicotine.

Nicotine is a highly addictive drug that induces a

constellation of pharmacologic effects, including activation of the dopamine reward pathway in the brain.

Tobacco use is complex, involving the interplay of a wide range of factors.

Treatment of tobacco use and dependence requires a multifaceted treatment approach.

(45)

ASSISTING PATIENTS

with QUITTING

(46)

WHY BOTHER?

Single-most effective strategy to lengthen and improve patients’ lives.

Quitting tobacco has immediate and long-term benefits for all patients.

It is inconsistent to provide health care and, at the same time, remain silent (or inactive) about a major health risk.

TOBACCO CESSATION

is an important component of PATIENT CARE.

(47)

Tobacco users expect to be encouraged to quit by health professionals.

Screening for tobacco use and providing tobacco cessation counseling are positively associated with patient satisfaction

(Barzilai et al., 2001; Conroy et al., 2005).

Barzilai et al. (2001). Prev Med 33:595–599; Conroy et al. (2005). Nicotine Tob Res 7 Suppl 1:S29–S34.

Failure to address tobacco use tacitly implies that quitting is not important.

WHY SHOULD CLINICIANS

ADDRESS TOBACCO?

(48)

TOBACCO DEPENDENCE:

A 2-PART PROBLEM

Tobacco Dependence

Treatment should address the physiological and the behavioral aspects of dependence.

Physiological Behavioral

Treatment Treatment

The addiction to nicotine

Medications for cessation

The habit of using tobacco

Behavior change program

(49)

EFFECTS of CLINICIAN INTERVENTIONS

1.0 1.1

1.7 2.2

n = 29 studies

Fiore et al. (2008). Treating Tobacco Use and Dependence: 2008 Update.

Clinical Practice Guideline. Rockville, MD: USDHHS, PHS.

With help from a clinician, the odds of quitting approximately double.

Compared to patients who receive no assistance from a clinician, patients who receive assistance are 1.7–2.2 times as likely to quit successfully for 5 or more months.

(50)

Estimated abstinence rate at 5+ months

1.0

1.8

2.5 2.4

n = 37 studies

The NUMBER of CLINICIAN TYPES CAN MAKE a DIFFERENCE, TOO

Compared to smokers who receive assistance from no clinicians, smokers who receive

assistance from two or more clinician types are 2.4–2.5 times as likely to quit successfully for 5 or more months.

Fiore et al. (2008). Treating Tobacco Use and Dependence: 2008 Update.

Clinical Practice Guideline. Rockville, MD: USDHHS, PHS.

(51)

WHY RESPIRATORY THERAPISTS?

Long-term relationships with many patients

Engender a sense of trust

Patients listen to what you have to say

Patients look to you for expert advice on issues concerning the lungs

Cessation can be discussed during the course of breathing treatments, etc.

You might be the ONE person who a patient listens to about smoking.

(52)

TOBACCO CESSATION

REQUIRES BEHAVIOR CHANGE

Fewer than 5% of people who quit without assistance are successful in quitting for more than a year

Few patients adequately PREPARE and PLAN for their quit attempt

Many patients do not understand the need to change behavior

Patients think they can just “make themselves quit”

Behavioral counseling is a key component of treatment for tobacco use and dependence.

(53)

Often, patients automatically smoke in the following situations:

Behavioral counseling helps patients learn to cope with these difficult situations without having a cigarette.

When drinking coffee

While driving in the car

When bored

While stressed

While at a bar with friends

After meals

During breaks at work

While on the telephone

While with specific friends or family members who use tobacco

BEHAVIOR CHANGE (cont’d)

(54)

The 5 A’s

ASK

about tobacco USE

ADVISE

tobacco users to QUIT

ASSESS

READINESS to make a quit attempt

ASSIST

with the QUIT ATTEMPT

ARRANGE

FOLLOW-UP care

(55)

ASK

about tobacco USE

ADVISE

tobacco users to QUIT

REFER

to other resources

ASSIST ARRANGE

BRIEF COUNSELING:

ASK, ADVISE, REFER

Patient receives assistance from other resources, with follow-up counseling arranged

(56)

about tobacco use

“If it’s OK with you, it would be helpful if we could talk about your tobacco use.”

“Do you, or does anyone in your household, ever smoke or use other types of tobacco or nicotine, such as e-

cigarettes?”

“We ask our patients about tobacco use, because it contributes to many medical conditions.”

“I take time to ask all of my patients about tobacco use—

because it’s important.”

ASK

STEP 1: ASK

(57)

tobacco users to quit (clear, strong, personalized)

“It’s important that you quit as soon as possible, and I can help you.”

“Cutting down while you are ill is not enough.”

“Occasional or light smoking is still harmful.”

“I realize that quitting is difficult. It is the most important thing you can do to protect your health now and in the future. I have training to help my patients quit, and when you are ready, I will work with you to design a specialized treatment plan.”

ADVISE

STEP 2: ADVISE

(58)

Consider asking:

“Do you ever plan to quit?”

“What might be some of the benefits of quitting now, instead of later?”

“What would have to change for you to decide to quit sooner?”

NOT READY TO QUIT:

COUNSELING STRATEGIES

If YES If NO

Advise patients to quit, and offer to assist (if or when

they change their mind).

Most patients will agree: There is no “good” time to quit, and there are benefits to quitting sooner as opposed to later.

Responses will reveal some of the barriers to quitting.

(59)

ADVISING PARENTS/CAREGIVERS

“Smoking outside, in the doorway, or in a separate room is not enough. The smoke

clings to your hair, clothes, and skin, and can irritate your child’s lungs and impair

breathing.”

“Quitting is the best thing you can do for the

your long-term health and that of your child.”

(60)

COUNSELING PARENTS WHO SMOKE

Explain connection between smoking and child’s illness in clear, matter-of-fact manner

Refer interested parents to the quitline or other cessation programs

For those not interested in quitting, offer suggestions to protect the child

Discuss progress at follow-up visits

(61)

COUNSELING PARENTS (cont’d)

Explain the connection:

“Your child has impaired lung function due to___.

Exposing him/her to second- or third-hand smoke causes additional problems.”

“Smoking outside or by the doorway is not sufficient, because the smoke clings to

clothes/hair.”

“For your child, the only safe amount of exposure

to smoke is none.”

(62)

COUNSELING PARENTS WHO ARE NOT INTERESTED IN QUITTING

Do not smoke in the car or in front of your child

Children who see parents smoke are more likely to smoke

Wear a “smoking jacket” and remove it when entering the home

Only removing exposed clothing and washing exposed skin/hair reduces risk

When handling infants:

Remove all clothing worn while smoking

Wash hands/hair first

(63)

ADDITIONAL

RECOMMENDATIONS

Explaining the link between smoking and symptoms is important, because most parents underestimate

The amount of exposure

The harm of exposure

Determine and modify exposure by other caregivers

Refer to cessation programs

Most parents are willing to modify exposure to some extent

(64)

FOLLOW-UP

For those patients seen multiple times:

Inform parents that you will be asking about their smoking behavior at each visit

Offer support and encouragement

Praise any change

Strategize solutions to challenges, as

appropriate

(65)

tobacco users to other resources Referral options:

A doctor, a nurse, a pharmacist, or another clinician, for additional counseling

A hospital-based group program

Web-based programs

The support program provided (at no cost) with each smoking cessation medication

The toll-free telephone quitline: 1-800-QUIT-NOW

REFER

STEP 3: REFER

(66)

Brief interventions have been shown to be effective

In the absence of time or expertise:

Ask, advise, and refer to other resources, such as local group programs or the toll-free quitline

1-800-QUIT-NOW

BRIEF COUNSELING:

ASK, ADVISE, REFER (cont’d)

This brief

intervention can be achieved in less

than 1 minute.

(67)

WHAT ARE

“TOBACCO QUITLINES”?

Tobacco cessation counseling, provided at no cost via telephone to all Americans

Staffed by highly trained specialists

Up to 4 – 6 personalized sessions (varies by state)

Some state quitlines offer pharmacotherapy at no cost (or reduced cost)

Up to 30% success rate for patients who complete sessions

Most health care providers, and most patients,

are not familiar with tobacco quitlines.

(68)

Caller is routed to language-appropriate staff

Brief questionnaire

Contact and demographic information

Smoking behavior

Choice of services

Individualized telephone counseling

Quitting literature mailed within 24 hr

Referral to local programs, as appropriate

WHEN a PATIENT CALLS the QUITLINE

Quitlines have broad reach and are recommended as an effective strategy in the 2008 Clinical Practice Guideline.

(69)

WEB-BASED PROGRAMS

www.becomeanex.org

www.quitnet.com

www.smokefree.gov

(70)

Address tobacco use

with all patients.

At a minimum,

make a commitment to incorporate brief tobacco interventions as part of routine patient care.

Ask, Advise, and Refer.

MAKE a COMMITMENT…

(71)

HELPING PATIENTS QUIT IS a CLINICIAN’S RESPONSIBILITY

THE DECISION TO QUIT LIES IN THE PATIENT’S HANDS.

TOBACCO USERS DON’T PLAN TO FAIL.

MOST FAIL TO PLAN.

Clinicians have a professional obligation to address tobacco use and can have

an important role in helping patients

plan for their quit attempts.

(72)

IF YOU DON’T SAY ANYTHING…

You inadvertently give patients…

a reason to smoke, and therefore a reason not to quit.

“How bad could my smoking be, if my respiratory therapist never said

anything to me?”

It is not necessary to conduct the entire cessation program, just get it started.

(73)

DR. GRO HARLEM BRUNTLAND,

FORMER DIRECTOR-GENERAL of the WHO:

“If we do not act decisively, a hundred years from now our grandchildren and their children will look back and

seriously question how people claiming to be committed to public health and social justice allowed the tobacco

epidemic to unfold unchecked.”

USDHHS. (2001). Women and Smoking: A Report of the Surgeon General. Washington, DC: PHS.

(74)

MEDICATIONS for

SMOKING CESSATION

(75)

TOBACCO DEPENDENCE:

A 2-PART PROBLEM

Tobacco Dependence

Treatment should address the physiological and the behavioral aspects of dependence.

Physiological Behavioral

Treatment Treatment

The addiction to nicotine

Medications for cessation

The habit of using tobacco

Behavior change program

(76)

Nicotine polacrilex gum

Nicorette (OTC)

Generic nicotine gum (OTC)

Nicotine lozenge

Nicorette Lozenge (OTC)

Nicorette Mini Lozenge (OTC)

Generic nicotine lozenge (OTC)

Nicotine transdermal patch

NicoDerm CQ (OTC)

Generic nicotine patches (OTC, Rx)

Nicotine nasal spray

Nicotrol NS (Rx)

Nicotine inhaler

Nicotrol (Rx)

Bupropion SR (Zyban, generic)

Varenicline (Chantix)

These are the only medications that are approved by the FDA for smoking cessation.

FDA-APPROVED MEDICATIONS

for CESSATION

(77)

PHARMACOTHERAPY

Fiore et al. (2008). Treating Tobacco Use and Dependence: 2008 Update.

Clinical Practice Guideline. Rockville, MD: USDHHS, PHS.

Medications significantly improve success rates.

* Includes pregnant women, smokeless tobacco users, light smokers, and adolescents.

“Clinicians should encourage all patients attempting to quit to use effective medications for tobacco

dependence treatment, except where contraindicated or for specific

populations* for which there is

insufficient evidence of effectiveness.”

(78)

PHARMACOTHERAPY:

USE in PREGNANCY

The Clinical Practice Guideline makes no recommendation regarding use of medications in pregnant smokers

Insufficient evidence of effectiveness

Category C: varenicline, bupropion SR

Category D: prescription formulations of NRT

“Because of the serious risks of smoking to the pregnant smoker and the fetus, whenever possible pregnant smokers should be offered

person-to-person psychosocial interventions that exceed minimal advice to quit.”

Fiore et al. (2008). Treating Tobacco Use and Dependence: 2008 Update.

Clinical Practice Guideline. Rockville, MD: USDHHS, PHS.

(79)

PHARMACOTHERAPY:

OTHER SPECIAL POPULATIONS

Pharmacotherapy is not recommended for:

Smokeless tobacco users

No FDA indication for smokeless tobacco cessation

Individuals smoking fewer than 10 cigarettes per day

Adolescents

Nonprescription sales (patch, gum, lozenge) are restricted to adults ≥18 years of age

NRT use in minors requires a prescription

Fiore et al. (2008). Treating Tobacco Use and Dependence: 2008 Update.

Clinical Practice Guideline. Rockville, MD: USDHHS, PHS.

Recommended treatment is behavioral counseling.

(80)

NICOTINE REPLACEMENT

THERAPY: RATIONALE for USE

Reduces physical withdrawal from nicotine

Eliminates the immediate, reinforcing effects of nicotine that is rapidly absorbed via tobacco smoke

Allows patient to focus on behavioral and psychological aspects of tobacco cessation

The use of NRT products approximately doubles quit rates.

(81)

PLASMA NICOTINE CONCENTRATIONS for NICOTINE-CONTAINING PRODUCTS

0 10 20 30 40 50 60 Time (minutes)

Cigarette

Moist snuff

(82)

Resin complex

Nicotine

Polacrilin

Sugar-free chewing gum base

Contains buffering agents to enhance buccal absorption of nicotine

Available: 2 mg, 4 mg; original, cinnamon, fruit and mint (various) flavors

NICOTINE GUM

Nicorette; generics

(83)

NICOTINE GUM: DOSING

Dosage is based on the “time to first cigarette”

(TTFC) as an indicator of nicotine dependence

Use the 2 mg gum:

If you smoke your first cigarette more than 30 minutes after waking Use the 4 mg gum:

If you smoke your first

cigarette of the day within 30 minutes of waking

(84)

NICOTINE GUM: DOSING

(cont’d)

Recommended Usage Schedule for Nicotine Gum Weeks 1–6 Weeks 7–9 Weeks 10–12 1 piece q 1–2 h 1 piece q 2–4 h 1 piece q 4–8 h

DO NOT USE MORE THAN 24 PIECES PER DAY.

(85)

NICOTINE GUM:

DIRECTIONS for USE

Chew each piece very slowly several times

Stop chewing at first sign of peppery taste or slight tingling in mouth (~15 chews, but varies)

“Park” gum between cheek and gum (to allow absorption of nicotine across buccal mucosa)

Resume slow chewing when taste or tingle fades

When taste or tingle returns, stop and park gum in different place in mouth

Repeat chew/park steps until most of the nicotine is gone (taste or tingle does not return; generally 30 minutes)

(86)

NICOTINE GUM:

CHEWING TECHNIQUE SUMMARY

Park between cheek & gum

Stop chewing at

first sign of peppery taste or tingling

sensation Chew slowly

Chew again when peppery taste or tingle fades

(87)

NICOTINE GUM: ADDITIONAL PATIENT EDUCATION

To improve chances of quitting, use at least nine pieces of gum daily

The effectiveness of nicotine gum may be reduced by some foods and beverages:

Coffee Juices

Wine Soft drinks

Do NOT eat or drink for 15 minutes BEFORE

or while using nicotine gum.

(88)

NICOTINE GUM:

ADD’L PATIENT EDUCATION

(cont’d)

Chewing gum will not provide same rapid satisfaction that smoking provides

Chewing gum too rapidly can cause excessive release of nicotine, resulting in

Lightheadedness

Nausea and vomiting

Irritation of throat and mouth

Hiccups

Indigestion

(89)

NICOTINE GUM:

ADD’L PATIENT EDUCATION

(cont’d)

Side effects of nicotine gum include

Mouth soreness

Hiccups

Dyspepsia

Jaw muscle ache

Nicotine gum may stick to dental work

Discontinue use if excessive sticking or damage to dental work occurs

(90)

NICOTINE GUM: SUMMARY

DISADVANTAGES

Need for frequent dosing can compromise adherence

Might be problematic for

patients with significant dental work

Proper chewing technique is necessary for effectiveness and to minimize adverse effects

Gum chewing might not be

acceptable or desirable for some patients

ADVANTAGES

Might serve as an oral substitute for tobacco

Might delay weight gain

Can be titrated to manage withdrawal symptoms

Can be used in

combination with other agents to manage

situational urges

(91)

NICOTINE LOZENGE

Nicorette Lozenge and Nicorette Mini Lozenge;

generics

Nicotine polacrilex formulation

Delivers ~25% more nicotine than equivalent gum dose

Sugar-free mint, cherry flavors

Contains buffering agents to enhance buccal absorption of nicotine

Available: 2 mg, 4 mg

(92)

NICOTINE LOZENGE: DOSING

Dosage is based on the “time to first cigarette”

(TTFC) as an indicator of nicotine dependence

Use the 2 mg lozenge:

If you smoke your first cigarette more than 30 minutes after waking

Use the 4 mg lozenge:

If you smoke your first

cigarette of the day within 30 minutes of waking

(93)

NICOTINE LOZENGE:

DOSING

(cont’d)

Recommended Usage Schedule for the Nicotine Lozenge

Weeks 1–6 Weeks 7–9 Weeks 10–12 1 lozenge

q 1–2 h

1 lozenge q 2–4 h

1 lozenge q 4–8 h

DO NOT USE MORE THAN 20 LOZENGES PER DAY.

(94)

NICOTINE LOZENGE:

DIRECTIONS for USE

Use according to recommended dosing schedule

Place in mouth and allow to dissolve slowly (nicotine release may cause warm, tingling sensation)

Do not chew or swallow lozenge

Occasionally rotate to different areas of the mouth

Lozenges will dissolve completely in about 2030

minutes

(95)

NICOTINE LOZENGE: ADDITIONAL PATIENT EDUCATION

To improve chances of quitting, use at least nine lozenges daily during the first 6 weeks

The lozenge will not provide the same rapid satisfaction that smoking provides

The effectiveness of the nicotine lozenge may be reduced by some foods and beverages:

 Coffee  Juices

 Wine  Soft drinks

Do NOT eat or drink for 15 minutes BEFORE

or while using the nicotine lozenge.

(96)

NICOTINE LOZENGE:

ADD’L PATIENT EDUCATION

(cont’d)

Side effects of the nicotine lozenge include

Nausea

Hiccups

Cough

Heartburn

Headache

Flatulence

Insomnia

(97)

NICOTINE LOZENGE: SUMMARY

DISADVANTAGES

Need for frequent dosing can compromise

adherence

Gastrointestinal side

effects (nausea, hiccups, heartburn) might be

bothersome

ADVANTAGES

Might serve as an oral substitute for tobacco

Use might delay weight gain

Can be titrated to manage withdrawal symptoms

Can be used in combination with other agents to manage situational urges

(98)

TRANSDERMAL NICOTINE PATCH

NicoDerm CQ; generic

Nicotine is well absorbed across the skin

Delivery to systemic circulation avoids hepatic first- pass metabolism

Plasma nicotine levels are lower and fluctuate less than with smoking

(99)

TRANSDERMAL NICOTINE PATCH:

PREPARATION COMPARISON

Product NicoDerm CQ Generic Nicotine

delivery

24 hours 24 hours

Availability OTC Rx/OTC

Patch strengths

7 mg 14 mg 21 mg

7 mg 14 mg 21 mg

(100)

TRANSDERMAL NICOTINE PATCH:

DOSING

Product Light Smoker Heavy Smoker

NicoDerm CQ

10 cigarettes/day

Step 2 (14 mg x 6 weeks) Step 3 (7 mg x 2 weeks)

>10 cigarettes/day Step 1 (21 mg x 6 weeks) Step 2 (14 mg x 2 weeks) Step 3 (7 mg x 2 weeks)

Generic

10 cigarettes/day

Step 2 (14 mg x 6 weeks) Step 3 (7 mg x 2 weeks)

>10 cigarettes/day Step 1 (21 mg x 4 weeks) Step 2 (14 mg x 2 weeks) Step 3 (7 mg x 2 weeks)

(101)

TRANSDERMAL NICOTINE PATCH:

DIRECTIONS for USE

Choose an area of skin on the upper body or upper outer part of the arm

Make sure skin is clean, dry, hairless, and not irritated

Apply patch to different area each day

Do not use same area again for at

least 1 week

(102)

TRANSDERMAL NICOTINE PATCH:

DIRECTIONS for USE

(cont’d)

Remove patch from protective pouch

Peel off half of the backing from patch

(103)

TRANSDERMAL NICOTINE PATCH:

DIRECTIONS for USE

(cont’d)

Apply adhesive side of patch to skin

Peel off remaining protective covering

Press firmly with palm of hand for 10 seconds

Make sure patch sticks well to skin, especially around edges

(104)

TRANSDERMAL NICOTINE PATCH:

DIRECTIONS for USE

(cont’d)

Wash hands: Nicotine on hands can get into eyes or nose and cause stinging or redness

Do not leave patch on skin for more than 24 hours—

doing so may lead to skin irritation

Adhesive remaining on skin may be removed with rubbing alcohol or acetone

Dispose of used patch by folding it onto itself, completely covering adhesive area

(105)

TRANSDERMAL NICOTINE PATCH:

ADDITIONAL PATIENT EDUCATION

Water will not harm the nicotine patch if it is applied correctly; patients may bathe, swim, shower, or exercise while wearing the patch

Do not cut patches to adjust dose

Nicotine may evaporate from cut edges

Patch may be less effective

Keep new and used patches out of the reach of children and pets

Remove patch before MRI procedures

(106)

TRANSDERMAL NICOTINE PATCH:

ADD’L PATIENT EDUCATION

(cont’d)

Side effects to expect in first hour:

Mild itching

Burning

Tingling

Additional possible side effects:

Vivid dreams or sleep disturbances

Headache

(107)

TRANSDERMAL NICOTINE PATCH:

ADD’L PATIENT EDUCATION

(cont’d)

After patch removal, skin may appear red for 24 hours

If skin stays red more than 4 days or if it swells or a rash appears, contact health care provider—do not apply new patch

Local skin reactions (redness, burning, itching)

Usually caused by adhesive

Up to 50% of patients experience this reaction

Fewer than 5% of patients discontinue therapy

Avoid use in patients with dermatologic conditions (e.g., psoriasis, eczema, atopic dermatitis)

(108)

TRANSDERMAL NICOTINE PATCH:

SUMMARY

DISADVANTAGES

When used as

monotherapy, cannot be titrated to acutely manage withdrawal symptoms

Not recommended for use by patients with

dermatologic conditions (e.g., psoriasis, eczema, atopic dermatitis)

ADVANTAGES

Once daily dosing

associated with fewer adherence problems

Of all NRT products, its use is least obvious to others

Can be used in

combination with other

agents; delivers consistent nicotine levels over 24 hrs

(109)

NICOTINE NASAL SPRAY

Nicotrol NS

Aqueous solution of nicotine in a 10-ml spray bottle

Each metered dose actuation delivers

50 mcL spray

0.5 mg nicotine

~100 doses/bottle

Rapid absorption across nasal mucosa

(110)

NICOTINE NASAL SPRAY:

DOSING & ADMINISTRATION

One dose = 1 mg nicotine

(2 sprays, one 0.5 mg spray in each nostril)

Start with 1–2 doses per hour

Increase prn to maximum dosage of 5 doses per hour or 40 mg (80 sprays; ~½ bottle) daily

For best results, patients should use at least 8 doses daily for the first 6–8 weeks

Termination:

Gradual tapering over an additional 4–6 weeks

(111)

NICOTINE NASAL SPRAY:

DIRECTIONS for USE

Press in circles on sides of bottle and pull to

remove cap

(112)

NICOTINE NASAL SPRAY:

DIRECTIONS for USE

(cont’d)

Prime the pump (before first use)

Re-prime (1-2 sprays) if spray not used for 24 hours

Blow nose (if not clear)

Tilt head back slightly and insert tip of bottle into nostril as far as comfortable

Breathe through mouth, and spray once in each nostril

Do not sniff or inhale while spraying

(113)

NICOTINE NASAL SPRAY:

DIRECTIONS for USE

(cont’d)

If nose runs, gently sniff to keep nasal spray in nose

Wait 2–3 minutes before blowing nose

Avoid contact with skin, eyes, and mouth

If contact occurs, rinse with water immediately

Nicotine is absorbed through skin and mucous membranes

(114)

NICOTINE NASAL SPRAY:

ADDITIONAL PATIENT EDUCATION

What to expect (first week):

Hot peppery feeling in back of throat or nose

Sneezing

Coughing

Watery eyes

Runny nose

Side effects should lessen over a few days

Regular use during the first week will help in development of tolerance to the irritant effects of the spray

If side effects do not decrease after a week,

contact health care provider

References

Related documents

For patients with chronic myeloid leukemia (CML) failing imatinib therapy, second-generation tyrosine kinase inhibitors (TKIs) are recommended.. Here, we describe two patients

The College of the Holy Cross is actively working to help increase the capacity of the South Worcester Neighborhood Improvement Corporation (SWNIC), and has guaranteed two loans

Conversely, 43.7% of all respondents who misused prescription drugs met criteria for alcohol dependence, problem gambling, and (or) had used illicit drugs in the past year..

Here, 8 incoming phone lines, and 16 outgoing stations are connected to a channel bank, which is connected to Asterisk using a T1 cross over cable.. (remember, in this diagram T1

the curriculum committees began their work using the Egyptian national skill standards that were recently developed through the National Skills Standard Project (NSSP) and that

My job isn't just about commercial lending, it's about creating a long lasting bond and managing every aspect of the banking relationship from Treasury Management and Merchant

A full 3D Computational Fluid Dynamics (CFD) model was recently created of the ALIP that, when used in combination with the magnetic model, could generate

Likewise, fully distributed flash flood warning systems capable of utilizing weather radar data are in the phase of operational testing (Georgakakos, et al. 1993), and